von Trinity, die q-1-zahlen. so müssen sie aussehen. die machen in einem quartal das 7-fache von calys-jahresumsatz:
Trinity Biotech Announces Quarter 1 Results Revenues Increase 29%
DUBLIN, Ireland, April 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- Trinity
Biotech plc (NASDAQ: TRIB) today announced results for the quarter ended March
31, 2005.
Revenues in the quarter increased 29.4% to US$21.2 million compared to
US$16.4 million in the same period last year. Revenues by key product area
were as follows :
Q1 2004 Q1 2005 % Increase
US$000 US$000
Infectious Disease 5,978 7,570 26.6
Coagulation 6,704 7,325 9.3
POC 1,821 3,026 66.2
Other 1,906 3,306 73.5
Total 16,409 21,227 29.4
Revenues by geographical location were as follows :
Q1 2004 Q1 2005 % Increase
US$000 US$000
USA 7,926 10,812 36.4
Europe 5,408 6,017 11.3
Asia / Africa 3,075 4,398 43.0
Total 16,409 21,227 29.4
Gross profit amounted to US$10.4 million, representing a gross margin of 49.0%.
This compares to a gross profit of US$8.0 million and a gross margin of 48.9% in
the same period last year.
R&D expenses have increased from US$1.2 million in Quarter 1 last year to US$1.3
million in the current quarter. The increase in SG&A costs from US$5.7 million
in Quarter 1 last year to US$7.2 million in the current year is primarily
attributable to the increased salesforce in the USA and increased costs
associated with the recent Adaltis and Fitzgerald acquisitions which were
acquired since Quarter 1 last year. However SG&A expenses have remained
relatively constant quarter on quarter at US$7.2 million.
The net effect of the above factors was an operating profit of US$1.44 million
for the quarter as compared to US$1.1 million in the same period last year and
an EPS of 1.8 US cents.
Commenting on the results, Rory Nealon, Chief Financial Officer, said "Our
quarterly revenues are showing strong growth in all segments and we are
particularly pleased with the 66% organic growth in Point of Care which is
almost entirely composed of sales of HIV. Overall the increase in our sales
would have been greater except for the fact that we are experiencing an
unusually quiet flu season.
Our business in the US has increased by 36% over the same period last year due
to a combination of increased revenues generated by our expanded salesforce and
the impact of the our acquisitions last year."
Ronan O'Caoimh, CEO commented, "At the end of the quarter we completed the
acquisition of Research Diagnostics Inc ("RDI"). RDI will be integrated into the
operations of Fitzgerald in the coming months and we anticipate that the
operation will be earnings positive post integration. RDI is a natural fit with
our existing operations in Fitzgerald in that it is particularly strong in
supplying product to research facilities worldwide whereas Fitzgerald's focus is
on diagnostic manufacturers.
We are pleased with the organic growth exhibited in all four business divisions.
Unigold HIV sales continue to grow both in the US and Africa while instrument
placements in both coagulation and infectious disease are gathering momentum.
These factors will drive growth in the coming quarters.
The Company today filed a US$75 million shelf registration statement with the
SEC. The Company has current cash balances of US$17.2 million and is not in due
diligence on any potential acquisition. We therefore have no current intention
of issuing equity. However, we have filed the shelf registration statement in
order that, in the event of issuing equity, we will issue registered as opposed
to unregistered shares - thereby reducing the requirement to issue shares at a
discount to the market price at the time. As stated in the past Trinity's goal
is to achieve revenues of US$250 million by 2009 through a combination of
organic growth and acquisitions. This shelf registration equips us better to
achieve that goal."
The quarterly conference call today will commence at 11 am EST (4pm GMT).
Investors can dial the following numbers to participate in the call.
|
Thread abonnieren
